Horizon Announces First Patient Enrolled in Diffuse Cutaneous Systemic Sclerosis Study
Dr. Dinesh Khanna, MD, MSc, Professor of Rheumatology and Medicine at the University of Michigan and coordinating investigator on this trial discusses the Phase 2b pivotal trial to evaluate Horizon Therapeutics’ HZN-825 to treat people with diffuse cutaneous systemic sclerosis (dcSSc).
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Treatment. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Treatment and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Treatment?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Dinesh Khanna, MD, MSc, Professor of Rheumatology and Medicine at the University of Michigan and coordinating investigator on this trial discusses the Phase 2b pivotal trial to …
- Key Point: Dinesh Khanna is a rheumatology specialist at the University of Michigan.
- Key Point: He directs a multidisciplinary group of caregivers, scientists, and clinical researchers dedicated to advancing knowledge about scleroderma and related conditions.
- Key Point: His research interests include developing new patient-reported outcome measures in patients with scleroderma and different diseases of the joint, and clinical trial design in ev…
- Key Point: In addition, he is leading international efforts to develop guidelines for the management of scleroderma and gout.
Dr. Dinesh Khanna is a rheumatology specialist at the University of Michigan. He directs a multidisciplinary group of caregivers, scientists, and clinical researchers dedicated to advancing knowledge about scleroderma and related conditions. His research interests include developing new patient-reported outcome measures in patients with scleroderma and different diseases of the joint, and clinical trial design in evaluating new treatments for scleroderma. In addition, he is leading international efforts to develop guidelines for the management of scleroderma and gout.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



